<p>阿尔法泰克控股公司（NASDAQ:ATEC - 获取免费报告）的股票目前被 12 位分析师给予了 “适度买入” 的平均推荐，MarketBeat Ratings 报告称。其中一位研究分析师给予该股票卖出评级，一位给予持有评级，十位给予买入评级。在过去一年中，更新了对该股票覆盖的券商的平均 12 个月目标价为 22.8182 美元。</p>
<p>最近，一些分析师对该公司发表了看法。Stifel Nicolaus 在 10 月 28 日的研究报告中开始覆盖阿尔法泰克，给予 “买入” 评级和 20.00 美元的目标价。摩根大通在 10 月 24 日的研究报告中开始覆盖阿尔法泰克，给予 “增持” 评级和 19.00 美元的目标价。Canaccord Genuity Group 在 10 月 31 日的研究报告中将阿尔法泰克的目标价从 20.00 美元上调至 25.00 美元，并给予公司 “买入” 评级。华尔街 Zen 在周六的研究报告中将阿尔法泰克的股票评级从 “持有” 上调至 “买入”。最后，Weiss Ratings 在 12 月 29 日的报告中重申了对阿尔法泰克股票的 “卖出（e+）” 评级。</p>
<p><strong>获取我们关于阿尔法泰克的最新研究报告</strong></p>
<h2>内部买卖</h2>
<p>在其他消息中，董事 David R. Pelizzon 在 12 月 16 日的交易中出售了 250,000 股阿尔法泰克股票。该股票以平均价格 19.66 美元出售，总交易额为 4,915,000.00 美元。出售后，该董事持有公司股票 10,395,045 股，估值约为 204,366,584.70 美元。此次交易使其持股比例减少了 2.35%。该交易在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站获取。此外，执行副总裁 Craig E. Hunsaker 在 12 月 10 日的交易中出售了 32,584 股该股票。该股票以平均价格 20.84 美元出售，总价值为 679,050.56 美元。交易完成后，该执行副总裁直接持有公司股票 1,256,558 股，估值为 26,186,668.72 美元。此次交易使其持股比例减少了 2.53%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士已出售公司股票 2,933,342 股，价值 60,928,781 美元。内部人士持有公司 22.80% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近调整了对该公司的持股。Emerald Advisers LLC 在第二季度将其在阿尔法泰克的持股增加了 3.8%。Emerald Advisers LLC 目前持有 1,684,334 股该医疗技术公司的股票，价值 18,696,000 美元，在此期间又增持了 60,885 股。Assenagon Asset Management S.A.在第三季度将其在阿尔法泰克的持股增加了 7,083.2%。Assenagon Asset Management S.A.目前持有 750,429 股该医疗技术公司的股票，价值 10,911,000 美元，在上个季度又增持了 739,982 股。American Century Companies Inc.在第二季度将其在阿尔法泰克的持股增加了 6.0%。American Century Companies Inc.目前持有 6,177,161 股该医疗技术公司的股票，价值 68,567,000 美元，在上个季度又购买了 347,130 股。Truist Financial Corp 在第二季度购买了阿尔法泰克的新头寸，价值约 216,000 美元。最后，Lisanti Capital Growth LLC 在第三季度获得了阿尔法泰克的新头寸，价值约 3,305,000 美元。66.35% 的股票由机构投资者和对冲基金持有。</p>
<h2>阿尔法泰克股价下跌 0.1%</h2>
<p>阿尔法泰克的股票在周一开盘价为 14.83 美元。阿尔法泰克的 1 年最低价为 8.81 美元，1 年最高价为 23.29 美元。该公司的 50 日移动平均线为 19.65 美元，200 日移动平均线为 16.97 美元。公司的债务与股本比率为 43.02，速动比率为 1.24，流动比率为 1.99。公司的市值为 22 亿美元，市盈率为-14.26，贝塔值为 1.01。</p>
<p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）最近在 10 月 30 日公布了季度财报。该医疗技术公司报告季度每股收益为 0.03 美元，超出分析师共识预期的（0.06 美元）0.09 美元。该公司季度收入为 1.965 亿美元，而共识预期为 1.8278 亿美元。在去年同期，该公司每股收益为（0.28 美元）。阿尔法泰克的季度收入同比增长 30.4%。分析师平均预计阿尔法泰克在本年度的每股收益为-1.08 美元。</p>
<h2>关于阿尔法泰克</h2>
<p>（获取免费报告）</p>
<p>阿尔法泰克控股公司 NASDAQ: ATEC 是一家医疗技术公司，专注于为退行性脊柱疾病的外科矫正设计、开发和商业化产品。公司的产品组合以体内植入物、生物材料、固定装置和手术规划工具为中心，旨在改善脊柱融合手术中的患者结果。阿尔法泰克的旗舰产品包括可定制的体内笼、骨移植材料和专门的仪器，旨在用于微创和开放脊柱手术。</p>
<p>阿尔法泰克成立于 1985 年，最初名为阿尔法泰克脊柱，2018 年更名为阿尔法泰克控股公司，已从单一产品组织发展成为脊柱市场的多平台创新者。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票比阿尔法泰克更好</li>
<li>特朗普刚刚签署了</li>
<li>一位前 CIA 官员关于特朗普的信息</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>新银行法#1582 可能为美国人解锁 21 万亿美元</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Alphatec 吗？</h2>
<p>在考虑 Alphatec 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Alphatec 并不在名单上。</p>
<p>虽然 Alphatec 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国医药设备 ETF - iShares

IBBQ

标普健康医疗设备 ETF - SPDR

阿尔法泰克控股

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>阿尔法泰克控股（NASDAQ:ATEC）获得了十二位分析师的 “适度买入” 共识评级。平均 12 个月目标价为 22.82 美元，其中十位分析师推荐买入，一位持有，一位卖出。最近的报道包括 Stifel Nicolaus 给予的买入评级，目标价为 20 美元，以及摩根大通给予的超配评级，目标价为 19 美元。内部交易显示出显著的销售，机构持股比例为 66.35%。该股票开盘价为 14.83 美元，市值为 22 亿美元，最近的财报显示收入同比增长 30.4%</p>

<p>Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the twelve analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $22.8182.</p>
<div class="lb-trans"><p>阿尔法泰克控股公司（NASDAQ:ATEC - 获取免费报告）的股票目前被 12 位分析师给予了 “适度买入” 的平均推荐，MarketBeat Ratings 报告称。其中一位研究分析师给予该股票卖出评级，一位给予持有评级，十位给予买入评级。在过去一年中，更新了对该股票覆盖的券商的平均 12 个月目标价为 22.8182 美元。</p>
</div><p>A number of analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on Alphatec in a research report on Tuesday, October 28th. They set a &#34;buy&#34; rating and a $20.00 price target on the stock. JPMorgan Chase &amp; Co. started coverage on Alphatec in a research note on Friday, October 24th. They set an &#34;overweight&#34; rating and a $19.00 price objective for the company. Canaccord Genuity Group raised their target price on Alphatec from $20.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Alphatec from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Alphatec in a report on Monday, December 29th.</p>
<div class="lb-trans"><p>最近，一些分析师对该公司发表了看法。Stifel Nicolaus 在 10 月 28 日的研究报告中开始覆盖阿尔法泰克，给予 “买入” 评级和 20.00 美元的目标价。摩根大通在 10 月 24 日的研究报告中开始覆盖阿尔法泰克，给予 “增持” 评级和 19.00 美元的目标价。Canaccord Genuity Group 在 10 月 31 日的研究报告中将阿尔法泰克的目标价从 20.00 美元上调至 25.00 美元，并给予公司 “买入” 评级。华尔街 Zen 在周六的研究报告中将阿尔法泰克的股票评级从 “持有” 上调至 “买入”。最后，Weiss Ratings 在 12 月 29 日的报告中重申了对阿尔法泰克股票的 “卖出（e+）” 评级。</p>
</div><p><strong>Get Our Latest Research Report on Alphatec</strong></p>
<div class="lb-trans"><p><strong>获取我们关于阿尔法泰克的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, Director David R. Pelizzon sold 250,000 shares of Alphatec stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the sale, the director owned 10,395,045 shares of the company's stock, valued at approximately $204,366,584.70. The trade was a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Craig E. Hunsaker sold 32,584 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $20.84, for a total value of $679,050.56. Following the completion of the transaction, the executive vice president directly owned 1,256,558 shares of the company's stock, valued at $26,186,668.72. This trade represents a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,933,342 shares of company stock valued at $60,928,781 in the last ninety days. Insiders own 22.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，董事 David R. Pelizzon 在 12 月 16 日的交易中出售了 250,000 股阿尔法泰克股票。该股票以平均价格 19.66 美元出售，总交易额为 4,915,000.00 美元。出售后，该董事持有公司股票 10,395,045 股，估值约为 204,366,584.70 美元。此次交易使其持股比例减少了 2.35%。该交易在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站获取。此外，执行副总裁 Craig E. Hunsaker 在 12 月 10 日的交易中出售了 32,584 股该股票。该股票以平均价格 20.84 美元出售，总价值为 679,050.56 美元。交易完成后，该执行副总裁直接持有公司股票 1,256,558 股，估值为 26,186,668.72 美元。此次交易使其持股比例减少了 2.53%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士已出售公司股票 2,933,342 股，价值 60,928,781 美元。内部人士持有公司 22.80% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the business. Emerald Advisers LLC grew its holdings in Alphatec by 3.8% during the second quarter. Emerald Advisers LLC now owns 1,684,334 shares of the medical technology company's stock worth $18,696,000 after acquiring an additional 60,885 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Alphatec by 7,083.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 750,429 shares of the medical technology company's stock valued at $10,911,000 after acquiring an additional 739,982 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Alphatec by 6.0% during the 2nd quarter. American Century Companies Inc. now owns 6,177,161 shares of the medical technology company's stock valued at $68,567,000 after purchasing an additional 347,130 shares in the last quarter. Truist Financial Corp bought a new position in shares of Alphatec during the 2nd quarter valued at about $216,000. Finally, Lisanti Capital Growth LLC acquired a new position in shares of Alphatec in the 3rd quarter worth approximately $3,305,000. 66.35% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。Emerald Advisers LLC 在第二季度将其在阿尔法泰克的持股增加了 3.8%。Emerald Advisers LLC 目前持有 1,684,334 股该医疗技术公司的股票，价值 18,696,000 美元，在此期间又增持了 60,885 股。Assenagon Asset Management S.A.在第三季度将其在阿尔法泰克的持股增加了 7,083.2%。Assenagon Asset Management S.A.目前持有 750,429 股该医疗技术公司的股票，价值 10,911,000 美元，在上个季度又增持了 739,982 股。American Century Companies Inc.在第二季度将其在阿尔法泰克的持股增加了 6.0%。American Century Companies Inc.目前持有 6,177,161 股该医疗技术公司的股票，价值 68,567,000 美元，在上个季度又购买了 347,130 股。Truist Financial Corp 在第二季度购买了阿尔法泰克的新头寸，价值约 216,000 美元。最后，Lisanti Capital Growth LLC 在第三季度获得了阿尔法泰克的新头寸，价值约 3,305,000 美元。66.35% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Alphatec Trading Down 0.1%</h2>
<div class="lb-trans"><h2>阿尔法泰克股价下跌 0.1%</h2>
</div><p>Alphatec stock opened at $14.83 on Monday. Alphatec has a 1 year low of $8.81 and a 1 year high of $23.29. The firm's 50-day moving average is $19.65 and its 200-day moving average is $16.97. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The company has a market cap of $2.20 billion, a P/E ratio of -14.26 and a beta of 1.01.</p>
<div class="lb-trans"><p>阿尔法泰克的股票在周一开盘价为 14.83 美元。阿尔法泰克的 1 年最低价为 8.81 美元，1 年最高价为 23.29 美元。该公司的 50 日移动平均线为 19.65 美元，200 日移动平均线为 16.97 美元。公司的债务与股本比率为 43.02，速动比率为 1.24，流动比率为 1.99。公司的市值为 22 亿美元，市盈率为-14.26，贝塔值为 1.01。</p>
</div><p>Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same period in the prior year, the company earned ($0.28) EPS. Alphatec's quarterly revenue was up 30.4% on a year-over-year basis. On average, equities analysts expect that Alphatec will post -1.08 earnings per share for the current year.</p>
<div class="lb-trans"><p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）最近在 10 月 30 日公布了季度财报。该医疗技术公司报告季度每股收益为 0.03 美元，超出分析师共识预期的（0.06 美元）0.09 美元。该公司季度收入为 1.965 亿美元，而共识预期为 1.8278 亿美元。在去年同期，该公司每股收益为（0.28 美元）。阿尔法泰克的季度收入同比增长 30.4%。分析师平均预计阿尔法泰克在本年度的每股收益为-1.08 美元。</p>
</div><h2>About Alphatec</h2>
<div class="lb-trans"><h2>关于阿尔法泰克</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.</p>
<div class="lb-trans"><p>阿尔法泰克控股公司 NASDAQ: ATEC 是一家医疗技术公司，专注于为退行性脊柱疾病的外科矫正设计、开发和商业化产品。公司的产品组合以体内植入物、生物材料、固定装置和手术规划工具为中心，旨在改善脊柱融合手术中的患者结果。阿尔法泰克的旗舰产品包括可定制的体内笼、骨移植材料和专门的仪器，旨在用于微创和开放脊柱手术。</p>
</div><p>Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.</p>
<div class="lb-trans"><p>阿尔法泰克成立于 1985 年，最初名为阿尔法泰克脊柱，2018 年更名为阿尔法泰克控股公司，已从单一产品组织发展成为脊柱市场的多平台创新者。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Alphatec</li>
<li>Trump just signed it</li>
<li>A Message From An Ex-CIA Officer About Trump</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>New Banking Law #1582 Could Unlock $21 Trillion for Americans</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比阿尔法泰克更好</li>
<li>特朗普刚刚签署了</li>
<li>一位前 CIA 官员关于特朗普的信息</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>新银行法#1582 可能为美国人解锁 21 万亿美元</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ATEC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alphatec Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Alphatec 吗？</h2>
</div><p>Before you consider Alphatec, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Alphatec 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Alphatec 并不在名单上。</p>
</div><p>While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alphatec 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿尔法泰克控股公司（NASDAQ:ATEC）被券商一致评为 “适度买入”